MANNKIND CORP
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
MNKD$4.19+7.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| (In thousands except share and per share data) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $74,882 | $46,339 |
| Short-term investments | 96,464 | 150,917 |
| Accounts receivable, net | 38,367 | 11,804 |
| Inventory | 35,313 | 27,886 |
| Prepaid expenses and other current assets | 46,553 | 31,360 |
| Total current assets | 291,579 | 268,306 |
| Restricted cash | 745 | 737 |
| Long-term investments | 5,012 | 5,482 |
| Property and equipment, net | 82,423 | 85,365 |
| Goodwill | 67,595 | 1,931 |
| Developed technology - on-body infusor | 190,027 | — |
| IPR&D - ReadyFlow Formulation | 129,600 | — |
| Other intangible assets | 5,072 | 5,265 |
| Other assets | 20,129 | 26,757 |
| Total assets | $792,182 | $393,843 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $9,034 | $6,792 |
| Accrued expenses and other current liabilities | 64,628 | 40,293 |
| Senior convertible notes – current | 36,280 | — |
| Liability for sale of future royalties – current | 14,298 | 12,283 |
| Contingent consideration - current | 21,132 | — |
| Financing liability – current | 10,328 | 10,062 |
| Deferred revenue – current | 15,331 | 12,407 |
| Total current liabilities | 171,031 | 81,837 |
| Liability for sale of future royalties – long term | 136,985 | 137,362 |
| Financing liability – long term | 93,092 | 93,877 |
| Deferred revenue – long term | 39,977 | 51,160 |
| Recognized loss on purchase commitments – long term | 65,952 | 58,204 |
| Operating lease liability | 10,689 | 11,645 |
| Contingent consideration – long term | 5,114 | — |
| Milestone liabilities | 2,003 | 2,523 |
| Term loan | 318,361 | — |
| Senior convertible notes | — | 36,051 |
| Total liabilities | 843,204 | 472,659 |
| Commitments and contingencies (Note 14) | ||
| Stockholders' deficit: | ||
| Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2025 or December 31, 2024 | — | — |
| Common stock, $0.01 par value – 800,000,000 shares authorized; 307,832,587 and 302,959,782 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 3,078 | 3,029 |
| Additional paid-in capital | 3,141,741 | 3,118,865 |
| Accumulated other comprehensive income | 115 | 1,109 |
| Accumulated deficit | (3,195,956) | (3,201,819) |
| Total stockholders' deficit | (51,022) | (78,816) |
| Total liabilities and stockholders' deficit | $792,182 | $393,843 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.